Absci Collaborates with Oracle and AMD to Speed up AI-Led Drug Discovery, Shares Jump

Tiger Newspress
09/11

Absci on Thursday announced a collaboration with Oracle Cloud Infrastructure and AMD to accelerate its AI-driven drug discovery efforts.

Absci shares jumped 9.5 in morning trading.

As part of the partnership, the Vancouver, Washington-based biotech will use Oracle’s AI infrastructure and AMD’s hardware for its generative AI Drug Creation Platform.

“This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows,” CEO Sean McClain remarked.

The announcement coincided with the Oracle Health and Life Sciences Summit taking place in Orlando, Florida, from Sept. 9 to 11.

During the event, the tech giant highlighted some of its healthcare-related advancements, including its AI capabilities within the Oracle Fusion Cloud Application, which it said could streamline supply chain operations within the industry.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10